Trial Profile
Effect of exenatide plus metformin vs. premixed human insulin aspart plus metformin on glycemic control and hypoglycemia in patients with inadequate control of type 2 diabetes on oral antidiabetic treatment.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Mar 2016
Price :
$35
*
At a glance
- Drugs Exenatide (Primary) ; Insulin aspart/insulin protamine aspart
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amylin Pharmaceuticals
- 29 Jun 2010 Results of the metformin only pretreatment arm were presented at the 70th Scientific Sessions of the American Diabetes Association.
- 22 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Sep 2009 Actual end date (August 2009) added as reported by ClinicalTrials.gov.